Submit Your Feeds

Business News • PR NewsWire • ARMO BioSciences Presents Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer at ESMO World Congress on Gastrointestinal Cancer 2017

ARMO BioSciences Presents Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer at ESMO World Congress on Gastrointestinal Cancer 2017
ARMO BioSciences Presents Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer at ESMO World Congress on Gastrointestinal Cancer 2017

REDWOOD CITY, Calif., June 29, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on...

View More : http://www.prnewswire.com/news-releases/armo-biosciences-presents-clinical-data-on-immunotherapy-am0010-in-advanced-panc...
Releted News by prnewswire
Trade Fair Certification for U.S. Pavilion at DenTech China 2017
ARMO BioSciences Presents Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer at ESMO World Congress on Gastrointestinal Cancer 2017
Castellum Builds the Nordic Region's First WELL-certified Building for SEKm 350
Home Sitemap Contact Us
© businessNewsNewsNews.com